New combination keeps inflammation down

Article

A new fixed combination of dexamethasone and netilmicin offers an effective and safe way to control ocular inflammation after cataract surgery.

A new fixed combination of dexamethasone and netilmicin offers an effective and safe way to control ocular inflammation after cataract surgery, according to results of a study published in the January issue of Eye.

S. Russo and colleagues from the Medical department at SIFI S.p.A, Italy and the Military Hospital, Romania, enrolled 223 patients to receive either I mg/ml dexamethasone plus 3 mg/ml netilmicin (n=148) or 1 mg/ml dexamethasone plus 3 mg/ml tobramycin (Tobradex) (n=75), four times a day for seven days after cataract surgery. Efficacy and safety were analysed one and seven days postoperatively, in addition to a follow-up visit 142 days postoperatively. The extent of anterior chamber inflammation, measured by slit-lamp according to a standard scoring system, was used as the primary efficacy parameter.

At seven days both fixed combinations were equally effective in reducing inflammation and the dexamethasone/netilmicin combination demonstrated a good safety profile, with no evidence of poor local tolerance or adverse reactions.

It was concluded that this new fixed combination is both effective and safe as a treatment for ocular inflammation following cataract surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.